Deutetrabenazine for tardive dyskinesia in people with intellectual disabilities
Part of Brain & nervous system, Mental health clinical trials.
This trial tests whether deutetrabenazine, a medication already used for tardive dyskinesia, can help people who also have intellectual or developmental disabilities. It aims to see if the drug reduces uncontrolled movements safely over 24 weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosis of intellectual or developmental disability (IQ below 70, started before age 22)
- Tardive dyskinesia for at least 3 months
- Stable doses of any psychiatric medications for the past 3 months and willing to keep them stable for 24 weeks
- No previous treatment with tetrabenazine, valbenazine, or deutetrabenazine
- No certain heart conditions or medications that could interact
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a drug called memantine can help people with Down syndrome. It aims to see if it's safe and if it improves memory or thinking.
This trial tests whether an oral medication, NBI-1065890, can reduce the involuntary muscle movements caused by long-term use of antipsychotic drugs. It is for adults with moderate to severe tardive dyskinesia who also have a stable mental health condition like schizophrenia or bipolar disorder.
This study tests if valbenazine helps adults with tardive dyskinesia whose symptoms continue even after taking or stopping another similar medication. Tardive dyskinesia involves uncontrollable movements from long-term use of certain mental health drugs.
This study looks at how patients with tardive dyskinesia (a movement disorder) engage with their condition and treatment. It is for people who have not yet had treatment for tardive dyskinesia.
This trial studies a treatment in people with intellectual disability and/or severe multiple disabilities. It may help participants and caregivers learn whether the treatment is safe and potentially beneficial for this group.
This study tests whether a non-invasive brain stimulation technique called repetitive transcranial magnetic stimulation (rTMS), targeted precisely using brain imaging, can safely reduce the involuntary movements caused by some psychiatric medications. If you have tardive dyskinesia, this treatment might help improve your motor symptoms.
Hear when a new Tardive Dyskinesia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.